COMMUNIQUÉS West-GlobeNewswire

Hemostemix Signs License Agreement with Aspire Health Science

23/02/2018 - 14:00

NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc . (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased [...]

Representatives of Fulgent Genetics to Participate in 2018 BTIG Healthcare Conference

23/02/2018 - 14:00

TEMPLE CITY, Calif., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT ) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief [...]

MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018

23/02/2018 - 14:00

WESTLAKE VILLAGE, Calif., Feb. 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD ) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will [...]

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

23/02/2018 - 14:00

Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease Crysvita Acknowledged by European Medicines Agency as an Outstanding Contribution to Public Health TOKYO and LONDON and NOVATO, [...]

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders

23/02/2018 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]

L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting

23/02/2018 - 13:30

RICHMOND HILL, Ontario, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP ) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates [...]

Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

23/02/2018 - 13:30

On track to file NDA before the end of March and anticipate a priority review Extended amikacin liposome inhalation suspension ( ALIS) intellectual property protection to 2035 with issuance of ninth U.S. patent [...]

Spark Therapeutics to Participate in Multiple Conferences in March

23/02/2018 - 13:30

PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Arlene V. [...]

Update: Montebello to distribute Biohit products in Norway

23/02/2018 - 13:07

Biohit Oyj Press release, February 23rd, 2018 at 10:00 a.m. local time (EET) Biohit Oyj and Montebello Diagnostics AS have signed an agreement for the distribution of Biohit diagnostic products in Norway. The contract [...]

Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

23/02/2018 - 13:01

Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN 2018 BTIG HEALTHCARE CONFERENCE Oxford, UK, 23 February 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug [...]

Surgery Partners Names Angela Justice Chief Human Resource Officer

23/02/2018 - 13:00

Newly created position highlights the importance of talent development to the Company’s long-term growth strategy Executive with extensive experience in building teams, effecting cultural change and driving business [...]

Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders

23/02/2018 - 13:00

CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth [...]

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

23/02/2018 - 13:00

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for [...]

Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

23/02/2018 - 13:00

OXFORD, United Kingdom, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, [...]

Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies

23/02/2018 - 13:00

HOUSTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

Avivagen Announces Two Year Distribution Agreement with PACC Pets and Attendance at Global Pet Expo

23/02/2018 - 12:30

OTTAWA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“ Avivagen ” or the “ Company ”), a life sciences innovation company with a series of patent protected products that support and [...]

Insider's tradings

23/02/2018 - 12:09

Nasdaq Copenhagen 23 February 2018 Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation art. 19 Coloplast is obliged to report on [...]

Digirad Corporation Reports Financial Results for the Fourth Quarter and Twelve Months Ended December 31, 2017

23/02/2018 - 12:00

Performs within guidance for Revenue and EBITDA for 2017 MDSS service contracts divestiture completed Company continues to pay regular quarterly dividend of $0.055 cents per share SUWANEE, Ga., Feb. 23, 2018 (GLOBE [...]

HMS Holdings Corp. Reports Fourth Quarter and Full Year 2017 Results

23/02/2018 - 12:00

4Q GAAP EPS of $0.30 Per Diluted Share / Full Year GAAP EPS of $0.47 Per Diluted Share 4Q Adjusted EPS of $0.49 Per Diluted Share / Full Year Adjusted EPS of $1.11 Per Diluted Share Federal Tax Law Changes Resulted in [...]